Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 18/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31020833 | 1.00 | NR1H2 (0.42) | NR1H2NR1H3MCL1CCNB2CDK1 | |
| SCHEMBL31694045 | 0.82 | NR1H2 (0.59) | NR1H2NR1H3 | |
| SCHEMBL1565970 | 0.82 | MCL1 (0.57) | NR1H2NR1H3MCL1CCNB2CDK1 | |
| SCHEMBL12803799 | 0.81 | NR1H2 (0.52) | NR1H2NR1H3 | |
| SCHEMBL1621434 | 0.81 | NR1H2 (0.43) | NR1H2NR1H3MCL1CCNB2CDK1 | |
| SCHEMBL23928865 | 0.81 | MCL1 (0.46) | MCL1 | |
| SCHEMBL13429972 | 0.80 | CCNB2 (0.42) | NR1H2NR1H3MCL1CCNB2CDK1 | |
| SCHEMBL22529438 | 0.79 | MCL1 (0.47) | NR1H2NR1H3MCL1CCNB2CDK1 | |
| SCHEMBL17236441 | 0.78 | NR1H2 (0.41) | NR1H2NR1H3MCL1CCNB2CDK1 | |
| SCHEMBL23928895 | 0.78 | CCNB2 (0.41) | NR1H2NR1H3MCL1CCNB2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112823157-B | Spirochroman derivatives | 吉瑞工厂 | 2024-08-09 | — | — | CN | disclosed |
| EP-3820869-B1 | SPIROCHROMANE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2023-08-30 | — | — | EP | disclosed |
| US-20210330650-A1 | SPIROCHROMANE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2021-10-28 | — | — | US | disclosed |
| CN-112823157-A | Spirochroman derivatives | 吉瑞工厂 | 2021-05-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210330650-A1 | SPIROCHROMANE DERIVATIVES | CHRNA7, CHRM3, ADRB3 | NR1H2 38/4885NR1H3 39/4885MCL1 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.